Selegiline: a Molecule with Innovative Potential

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2019 Sep 29

PMID 31562557

Citations 27

Authors

Tamas Tabi

Laszlo Vecsei

Moussa B Youdim

Peter Riederer

Eva Szoko

Affiliations

Soon will be listed here.

Abstract

Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson's disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on-off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson's disease. However, the serious side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors.

Citing Articles

Inhibition of 5-hydroxyindoleacetic acid to reduce neutrophil extracellular trap production improves lung condition in chronic obstructive pulmonary disease mice.

Zeng Q, Xue L, Li W, Liang C, Zhou W, Xiong W Ann Med. 2025; 57(1):2474734.

PMID: 40066951 PMC: 11899248. DOI: 10.1080/07853890.2025.2474734.

The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation.

Velickovic U, Selakovic D, Jovicic N, Mitrovic M, Janjic V, Rosic S Biomedicines. 2025; 13(2).

PMID: 40002925 PMC: 11853207. DOI: 10.3390/biomedicines13020512.

Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012-2024).

Alsaad I, Abdel Rahman D, Al-Tamimi O, Alhaj S, Sabbah D, Hajjo R Molecules. 2025; 30(1.

PMID: 39795182 PMC: 11722196. DOI: 10.3390/molecules30010126.

Therapeutic drug monitoring in Parkinson's disease.

Muller T, Gerlach M, Hefner G, Hiemke C, Jost W, Riederer P J Neural Transm (Vienna). 2024; 131(10):1247-1262.

PMID: 39227478 PMC: 11489222. DOI: 10.1007/s00702-024-02828-5.

Asymmetric N-oxidation catalyzed by bisguanidinium dinuclear oxodiperoxomolybdosulfate.

Wu W, Ang E, Xu X, Wang Q, Wang H, Lee R Nat Commun. 2024; 15(1):7317.

PMID: 39183335 PMC: 11345438. DOI: 10.1038/s41467-024-51765-0.

References

BURKE W, Roccaforte W, Wengel S, Bayer B, Ranno A, Willcockson N . L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc. 1993; 41(11):1219-25. DOI: 10.1111/j.1532-5415.1993.tb07306.x. View

Birkmayer W . Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1983; 95:103-5. DOI: 10.1111/j.1600-0404.1983.tb01522.x. View

Riederer P, Muller T . Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018; 125(11):1751-1757. DOI: 10.1007/s00702-018-1876-2. View

Szoko E, Tabi T, Riederer P, Vecsei L, Magyar K . Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. J Neural Transm (Vienna). 2018; 125(11):1735-1749. DOI: 10.1007/s00702-018-1853-9. View

Teo K, Ho S . Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Transl Neurodegener. 2013; 2(1):19. PMC: 3847108. DOI: 10.1186/2047-9158-2-19. View

. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View

Biberman R, Neumann R, Katzir I, Gerber Y . A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003; 98(10):1403-7. DOI: 10.1046/j.1360-0443.2003.00524.x. View

Mann J, Aarons S, Wilner P, Keilp J, Sweeney J, Pearlstein T . A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989; 46(1):45-50. DOI: 10.1001/archpsyc.1989.01810010047007. View

Larsen J, BOAS J, Erdal J . Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol. 1999; 6(5):539-47. DOI: 10.1046/j.1468-1331.1999.650539.x. View

10.

Riederer P, Laux G . MAO-inhibitors in Parkinson's Disease. Exp Neurobiol. 2011; 20(1):1-17. PMC: 3213739. DOI: 10.5607/en.2011.20.1.1. View

11.

Szende B, Magyar K, Szegedi Z . Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology (Bp). 2001; 8(3-4):249-55. View

12.

Gerlach M, Youdim M, Riederer P . Pharmacology of selegiline. Neurology. 1996; 47(6 Suppl 3):S137-45. DOI: 10.1212/wnl.47.6_suppl_3.137s. View

13.

Bodkin J, Amsterdam J . Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002; 159(11):1869-75. DOI: 10.1176/appi.ajp.159.11.1869. View

14.

Brannan T, Yahr M . Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol. 1995; 37(1):95-8. DOI: 10.1002/ana.410370117. View

15.

Kahn R, Gorgon L, Jones K, McSherry F, Glover E, Anthenelli R . Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res. 2011; 14(3):377-82. PMC: 3281235. DOI: 10.1093/ntr/ntr143. View

16.

Shin H . Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997; 25(6):657-62. View

17.

Glover V, Sandler M, Owen F, Riley G . Dopamine is a monoamine oxidase B substrate in man. Nature. 1977; 265(5589):80-1. DOI: 10.1038/265080a0. View

18.

Birkmayer W, Riederer P, AMBROZI L, Youdim M . Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977; 1(8009):439-43. DOI: 10.1016/s0140-6736(77)91940-7. View

19.

Lighezan R, Sturza A, Duicu O, Ceausu R, Vaduva A, Gaspar M . Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease. Can J Physiol Pharmacol. 2016; 94(10):1040-1047. DOI: 10.1139/cjpp-2015-0580. View

20.

. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328(3):176-83. DOI: 10.1056/NEJM199301213280305. View